Hígado Graso (NASH)
Aug 18, 2026
Insulin resistance drives GGT elevation in MASLD with diabetes: evidence from clinical cohorts, mendelian randomization and functional genomics
Causal Mechanics of Hyperinsulinemia-Driven Gamma-Glutamyltransferase Elevation in MASLD and Type 2 Diabetes: A Sex-Dimorphic Functional Genomics Perspective
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) concurrently presenting with type 2 diabetes mellitus (T2DM) represents a major global health burden characterized by accelerated hepatic injury and systemic metabolic decompensation. While serum gamma-glutamyltransferase (GGT) has historically served as a non-specific surrogate marker for hepatobiliary stress, integrated functional genomics and Mendelian randomization (MR) analyses demonstrate that insulin resistance (IR) actively drives GGT upregulation. Mechanistically, hyperinsulinemia and lipotoxicity trigger endoplasmic reticulum stress, mitochondrial reactive oxygen species (ROS) hyperproduction, and intracellular glutathione (GSH) depletion. To counter oxidative stress, hepatic membrane-bound GGT expression is transcriptionally upregulated via Nrf2 pathways to facilitate extracellular GSH cleavage and amino acid recycling. Crucially, this axis exhibits striking biological sex differences: estrogenic signaling via estrogen receptor-alpha (ERα) mitigates hepatic lipotoxicity, enhances basal antioxidant reserves, and tempers GGT elevation in premenopausal females. Conversely, androgenic signaling and postmenopausal estrogen withdrawal exacerbate hepatic IR and GGT shedding. Unraveling these sex-dimorphic cellular mechanisms is essential for establishing stratified biomarker panels and targeted precision therapies for MASLD in diabetic populations.
Introduction & Cellular Mechanisms
The paradigm of metabolic dysfunction-associated steatotic liver disease (MASLD) has shifted from a passive hepatic manifestation of metabolic syndrome to an active driver of systemic metabolic deregulation. In patients with concurrent type 2 diabetes mellitus (T2DM), severe hepatic insulin resistance (IR) promotes unchecked de novo lipogenesis (DNL) via sterol regulatory element-binding protein 1c (SREBP-1c) activation, alongside impaired suppression of gluconeogenesis mediated by persistent Forkhead box O1 (FOXO1) signaling. The consequent accumulation of lipotoxic lipid species—specifically diacylglycerols (DAGs) and ceramides—activates novel protein kinase C isoforms (PKCε), blunting insulin receptor substrate 1/2 (IRS-1/2) phosphorylation and locking hepatocytes in a feed-forward cycle of IR.
```
Lipotoxicity (DAGs, Ceramides) ➔ PKCε Activation ➔ Suppressed IRS-1/2 ➔ Severe Hepatic IR
│
▼
GGT Expression ◄── Nrf2 Activation ◄── GSH Depletion ◄── ER Stress & ROS ◄── Hyperinsulinemia
```
Triangulated evidence from clinical cohorts, functional genomics, and bidirectional Mendelian randomization (MR) refutes the traditional view that elevated serum gamma-glutamyltransferase (GGT) is merely an epiphenomenon of hepatocyte necrosis. Instead, causal genetic inference confirms that severe hyperinsulinemia directly drives hepatic GGT transcription and membrane shedding. At the organelle level, severe IR leads to electron transport chain overload within mitochondria, inducing electron leakage at Complexes I and III, and triggering severe endoplasmic reticulum (ER) stress through the unfolded protein response (UPR) pathway (PERK-eIF2α and IRE1α arms).
To compensate for the elevated production of reactive oxygen species (ROS) and maintain intracellular glutathione (GSH) homeostasis, hepatocytes recruit the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor. Nrf2 binds to antioxidant response elements (AREs) in the promoter region of the *GGT1* gene, inducing the synthesis of membrane-bound GGT. Membrane-bound GGT catalyzes the extracellular cleavage of GSH into cysteinylglycine and glutamate, driving the re-uptake of cysteine precursors needed for intracellular GSH resynthesis. Consequently, elevated circulating GGT reflects an overloaded hepatic adaptive response to hyperinsulinemia-induced oxidative stress and perturbed GSH dynamics.
Sex-Dimorphic Regulation & Translational Implications
Sex-and-gender-based analysis (SGBA) reveals that the molecular cross-talk between insulin resistance, glutathione turnover, and GGT regulation is strongly modulated by biological sex and hormonal status.
1. Hormonal Modulation of Hepatic Insulin Sensitivity and ROS Dynamics: Estrogen (17β-estradiol, E2), acting via hepatic estrogen receptor-alpha (ERα), exerts a potent protective effect against hyperinsulinemia-driven lipotoxicity. E2-ERα signaling downregulates *SREBP-1c* expression, enhances mitochondrial fatty acid beta-oxidation through PPARα co-activation, and directly reduces ROS production. Consequently, premenopausal females demonstrate lower baseline induction of GGT relative to age-matched males with equivalent body mass index (BMI), owing to superior intrinsic antioxidant capacity and preserved hepatic insulin sensitivity.
2. Impact of Androgenic Profiles and Postmenopausal Transition: Males exhibit higher baseline activity of microsomal GGT and an increased susceptibility to hepatic DAG accumulation, which sensitizes the liver to hyperinsulinemia-driven oxidative stress. In females, the postmenopausal transition marks a critical shift: loss of circulating E2 leads to visceral fat redistribution, downregulates hepatic ERα target genes, and induces an abrupt increase in severe MASLD susceptibility. Postmenopausal women display accelerated rates of GGT elevation and MASH progression, mirroring the high-risk metabolic trajectory observed in diabetic males.
3. Precision Biomedicine and Diagnostic Stratification: The sex-specific calibration of GGT cut-offs is essential for clinical practice. Utilizing uniform diagnostic thresholds obscures early-stage MASLD in premenopausal females while potentially overestimating advanced fibrosis risk in older males. Integrating sex-stratified Mendelian randomization targets with transcriptomic panels allows for the identification of female-specific and male-specific metabolic sub-phenotypes, paving the way for tailored insulin-sensitizing and antioxidant therapeutic strategies.
Conclusions & Clinical Outlook
Functional genomics and Mendelian randomization conclusively position insulin resistance as an active, causal upstream driver of hepatic GGT elevation in MASLD complicated by diabetes. GGT elevation is an enzymatic compensatory mechanism linked to organelle oxidative stress and hepatic glutathione turnover. The integration of sex-and-gender-based analysis highlights the protective role of estrogenic signaling in dampening this pathway, contrasting with the heightened vulnerability observed in postmenopausal females and males. Translating these findings into clinical practice requires sex-calibrated biomarker panels for MASLD screening and the development of targeted therapies capable of modulating the hepatic IR-Nrf2-GGT axis. Future translational research must prioritize sex-stratified clinical trials to refine precision interventions for metabolic liver diseases.
